Urine MT protein and application of polypeptide fragment thereof in gout

Through the detection of MT protein and its peptide fragments in urine, the problems of high false negative rates and poor compliance in gout diagnosis are solved, and non-invasive and accurate gout diagnosis and monitoring methods are provided, which improves the accuracy of early diagnosis and condition evaluation. .

CN118897083APending Publication Date: 2024-11-05张曼
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310492736.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-05
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing gout diagnosis methods have high false negative rates and poor compliance, especially in early diagnosis and self-limiting attacks, and lack effective non-invasive markers.

Method used

Through the detection of MT protein and its peptide fragments in urine, a urine protein polypeptide map was established using liquid phase secondary mass spectrometry technology, and it was found that the expression of MT protein and its peptide fragments in gout increased in patients with gout, and it was developed for the diagnosis of gout. Kits for differential diagnosis, condition degree judgment, treatment effect evaluation, monitoring and prognosis evaluation.

Benefits of technology

Non-invasive and resampled urine specimen detection has been achieved, which has improved the accuracy and compliance of early diagnosis of gout, and can effectively distinguish between active and inactive periods of gout, and evaluate the progress of the disease and treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118897083A_ABST
    Figure CN118897083A_ABST
Patent Text Reader

Abstract

The invention provides application of urine metallothionein (MT) and polypeptide fragments thereof, and particularly relates to application of urine MT protein and polypeptide fragments thereof in preparation of preparations for gout diagnosis, differential diagnosis, illness degree judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like. Researches prove that compared with healthy people and hyperuricemia subjects, the expression of urine MT protein and polypeptide fragments of the urine MT protein in gout patients is increased, and compared with gout inactive-stage patients, the expression of the urine MT protein and the polypeptide fragments of the urine MT protein in gout active-stage patients is increased. The method can be used for various purposes of application detection of gout patients. The advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of a urine sample are exerted, and the urine MT protein and the polypeptide fragment thereof are detected by utilizing the urine sample.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to new uses of urine MT protein and polypeptide fragments thereof, and specifically to the use of urine MT protein and polypeptide fragments thereof in preparations for gout diagnosis, differential diagnosis, disease severity assessment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research. Background Art

[0002] Gout is a common disease caused by the deposition of sodium urate crystals in joints or non-joint parts, which causes severe intermittent joint pain. The incidence is increasing in both developed and developing countries. The incidence of gout is 0.6-2.9‰ / year, and the incidence in adults is 0.68%-3.8%. At present, the diagnosis of gout mainly relies on serum uric acid determination and imaging methods to find sodium urate crystals deposited in joint effusions or tophi. Imaging methods such as DECT have certain false negatives, especially for small sodium urate crystals and low-density crystals. In some cases, the serum uric acid concentration is normal when gouty arthritis symptoms occur. In addition, gout attacks are self-limiting and spontaneously relieved. The current diagnostic methods are lagging, especially for early gout patients. The gold standard for gout is still to use a microscope to confirm the presence of sodium urate crystals in synovial fluid or tophi. However, this examination is an invasive examination after all, and the patient's compliance is poor. Therefore, new predictive markers with good patient compliance are urgently needed to diagnose gout in a timely manner.

[0003] Metallothionein (MT) is a small cysteine-rich protein that can bind to metal ions. It plays a role in maintaining metal ion homeostasis, regulating physiological heavy metal detoxification, DNA damage, and oxidative stress. Therefore, MT protein has attracted much attention as a factor related to immune homeostasis regulation. Recent studies have shown that various MT isomers, especially MT1, play an important role in immunoregulatory functions in tumors, infectious diseases, central nervous system diseases, autoimmune diseases, and inflammatory bowel diseases. MT protein is involved in the pathogenesis of inflammatory diseases. In rheumatoid arthritis, MT1 protein expression is significantly upregulated and is closely related to rheumatoid arthritis. Studies have found that MT1 is closely related to the occurrence and pathogenesis of osteoarthritis (OA). The elevated level of MT1 in invasive inflammatory osteoarthritis is higher than that in primary osteoarthritis and normal control groups. MT protein levels are positively correlated with visual analogue scores, CRP, and erythrocyte sedimentation rate. In synovial cells, MT1 is positively correlated with IL-1B, TNF-a, and IL-6, indicating that MT1 may be involved in the inflammatory regulation of OA. In multiple sclerosis (MS), clinical data show that the expression levels of MT1 and MT2 are significantly increased in MS patients with brain damage, and the expression level of MT in MS patients in the inactive group is significantly higher than that in active MS patients, indicating that MT protein may be involved in the remission of MS disease. In addition, MT1 and MT2 are also expressed in the preclinical animal model of MS, autoimmune cerebrospinal meningitis (EAE). Therefore, it can be used to predict the clinical signs of MS. MT protein is involved in the occurrence and development of inflammatory diseases.

[0004] Urine comes directly from the kidneys. The occurrence and development of gout is closely related to the production and excretion of uric acid produced by abnormal purine metabolism. The kidneys are an important organ for uric acid excretion. At the same time, urine is an ultrafiltrate of blood. Markers of gout occurrence and development will inevitably appear in urine. Therefore, the study of urinary biomarkers of gout is of great value in the early diagnosis of gout, prediction of active attacks and prognosis evaluation, but there are few studies on urinary biomarkers that can reflect gout. Urine is an ultrafiltrate of blood. It has the advantages of being easy to obtain, non-invasive, and repeatable sampling, and patients have good compliance. Therefore, it provides an ideal source of specimens for the diagnosis of gout patients and even for finding markers for early diagnosis. Summary of the invention

[0005] The purpose of the present invention is to provide an application of urine MT protein and polypeptide fragments thereof in the preparation of preparations for gout diagnosis, differential diagnosis, disease severity judgment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research.

[0006] Preferably, the amino acid sequence of the urine MT protein includes that shown in SEQ ID NO.1 (1 mdpncscttgvscactgsck ckeckctsck ksccsccpvg cakcahgcvc kgtlencscc 61 a); Or an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO.1 and having the same function as the amino acid sequence shown in SEQ ID NO.1.

[0007] Preferably, the preparation is a kit for detecting MT protein and its polypeptide fragments in urine of gout patients.

[0008] Preferably, the kit includes one or more of an immunological method for antigen-antibody reaction and a kit thereof, such as an aptamer antibody or an antibody fragment that can specifically bind to MT and a polypeptide fragment thereof.

[0009] Preferably, the detection method includes mass spectrometry and other methods for directly detecting MT and its polypeptide fragments and related kits.

[0010] Preferably, the detection method includes methods such as direct detection of MT and its polypeptide fragments and related nucleic acid detection methods and related kits.

[0011] Preferably, the kit further comprises components selected from the following group: any one or a combination of solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody, second antibody diluent, luminescent reagent, washing solution, color developing solution and stop solution.

[0012] Preferably, the standard substances include MT standard substances and humanized tag antibody standard substances; preferably, the quality control substances include: MT quality control substances and humanized tag antibody quality control substances; preferably, the solid phase carrier includes: microparticles, microspheres, glass slides, test strips, plastic beads, liquid chips, microplates or affinity membranes, etc. and other carriers with equivalent functions.

[0013] Preferably, the material of the solid phase carrier is any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.

[0014] The inventors first collected urine specimens from the hyperuricemia gout group, the simple hyperuricemia group, and the healthy group, established a urine protein peptide map by liquid chromatography tandem mass spectrometry (LC-MS / MS), and finally obtained the differential protein MT through bioinformatics analysis.

[0015] The present invention confirms through research that compared with healthy people and hyperuricemia subjects, the expression of MT protein and its polypeptide fragments in urine of gout patients is increased, and compared with patients in the inactive stage of gout, the expression of MT protein and its polypeptide fragments in urine is increased in patients in the active stage of gout. Therefore, it is proposed that the detection of MT protein and its polypeptide fragments in urine can be used for the diagnosis, differential diagnosis, judgment of the severity of the disease, evaluation of the treatment effect, monitoring, prognosis assessment and mechanism research of gout.

[0016] The present invention takes advantage of the non-invasive acquisition of urine specimens, large-scale repeated sampling, and convenient storage, and utilizes urine specimens to detect urine MT protein and its polypeptide fragments.

[0017] In order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, preferred embodiments are given below and described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is the content of urinary MT protein and its polypeptide fragments in healthy people, simple hyperuricemia, and hyperuricemia gout patients. (MT-NC healthy people group; MT-H simple hyperuricemia group; MT-G hyperuricemia gout group) Figure 2 This is a graph showing the levels of urinary MT protein and its polypeptide fragments in patients with inactive gout and active gout.

[0019] Figure 3 The ROC curve was drawn to compare the gout group with the normal group.

[0020] Figure 4 ROC curve was drawn between the gout active group and the gout inactive group. Implementation

[0021] Example 1 Urine specimen collection and processing Healthy people, patients with simple hyperuricemia, and patients with hyperuricemia and gout were selected as subjects. Fresh morning urine samples were collected from each group of subjects after admission and placed in a dry, clean container. Then, the samples were centrifuged at 1500g for 10 minutes to remove cell debris. Then, the samples were placed in a -80°C refrigerator until further analysis.

[0022] Example 2 Urine peptide mass spectrometry analysis The urine samples were subjected to protein extraction and enzymatic desalination, and the extracted protein concentration was measured. The urine protein peptide maps of the three groups of subjects were constructed using advanced liquid chromatography-mass spectrometry (LC-MS / MS).

[0023] Example 3 Differential peptide data analysis All experiments were performed three times, and all values ​​are expressed as mean ± standard deviation. The analysis results of differentially expressed proteins were obtained by fold change 1.2. P A value <0.05 was considered statistically significant, and differentially expressed proteins were screened, and global cluster analysis was performed on the target proteins.

[0024] Example 4 Verification of urine MT protein Compared with healthy people and hyperuricemia subjects, the expression of urinary MT protein and its polypeptide fragments in gout patients was increased, and compared with patients with inactive gout, the expression of urinary MT protein and its polypeptide fragments was increased in patients with active gout.

[0025] Although the present invention has been disclosed as above in terms of preferred embodiments, it is not intended to limit the present invention. Any technician in the relevant technical field may make some changes and improvements without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention shall be based on what is defined in the claims.

Claims

1. Application of urine MT protein and its polypeptide fragments in the preparation of preparations for gout diagnosis, differential diagnosis, disease severity assessment, treatment effect evaluation, monitoring, prognosis assessment and mechanism research.

2. The use according to claim 1, characterized in that: The amino acid sequence of the urine MT protein is shown in SEQ ID NO.1; The use according to claim 1 is characterized in that the preparation is a kit for detecting MT protein and its polypeptide fragments in urine of gout patients.

3. The use according to claim 3, characterized in that: The kit includes an immunological method of antigen-antibody reaction and a kit thereof, such as one or more of aptamer antibodies or antibody fragments that can specifically bind to MT and its polypeptide fragments.

4. The use according to claim 3, characterized in that: The detection method includes a mass spectrometry method for directly detecting MT and its polypeptide fragments and related kits.

5. The use according to claim 3, characterized in that: The detection method includes methods such as direct detection of MT and its polypeptide fragment-related nucleic acid detection and related kits.

6. The use according to claim 3, characterized in that: The kit also includes components selected from the following group: any one or a combination of solid phase carrier, diluent, reference substance, standard substance, quality control substance, detection antibody, second antibody, second antibody diluent, luminescent reagent, washing solution, color developing solution, and stop solution.

7. The use according to claim 7, characterized in that: The standard products include MT standard products and humanized tag antibody standard products; Preferably, the quality control products include: MT quality control products, humanized tag antibody quality control products; preferably, the solid phase carrier includes: microparticles, microspheres, glass slides, test strips, plastic beads, liquid chips, microplates or affinity membranes, etc. and other carriers with equivalent functions.

8. The use according to claim 8, characterized in that: The material of the solid phase carrier is any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose and carriers with similar functions.